Alligator Bioscience Stock Plummets 73% After Halting Lead Cancer Drug Development

Shares of Alligator Bioscience (ATORX) plunged by more than 73% on Tuesday after the company's board of directors announced a halt to the independent development of its lead drug candidate, mitazalimab, for pancreatic cancer. The company also unveiled plans for an urgent and substantial capital raise, signaling immediate funding needs and causing severe dilution for existing shareholders.

Strategic Pivot Halts Key Program

The decision, announced at 08:17 CEST, marks a dramatic reversal for what the company called the "cornerstone" of its clinical pipeline. Alligator Bioscience cited the "rapid evolution in the pancreatic cancer treatment landscape" as the reason why pursuing an in-house Phase 3 trial for mitazalimab was no longer tenable. This comes despite the drug previously achieving Phase 2 trial successes and receiving regulatory endorsements from the FDA and EMA.

Following the announcement, Alligator will pivot its strategy to seek an out-licensing or divestiture partner for the mitazalimab asset. The company plans to redirect its internal resources toward its economic interest in HLX22, an anti-HER2 antibody being developed by Shanghai Henlius Biotech, which requires no further funding from Alligator.

Urgent Capital Raise Signals Pressure

Ad

Compounding the negative pipeline news, Alligator Bioscience announced a proposed rights issue to raise approximately SEK 125.6 million in new capital. The plan is subject to shareholder approval at an extraordinary general meeting scheduled for August 26, 2026. The company also secured bridge loans to fund its operations in the interim, underscoring the urgency of its financial situation.

For investors, the combination of abandoning a primary clinical catalyst and the prospect of significant share dilution created a perfect storm. The capital raise, while necessary for survival, drastically reduces the value of existing shares, which contributed to the intense selling pressure throughout the trading session.

Market Reaction

The market's response was swift and severe. Alligator's stock fell 73.6% to trade at SEK 0.0513, hitting a new 52-week low of SEK 0.0324 intraday. This is a stark contrast to its 52-week high of SEK 6.04, highlighting how decisively the market has repriced the company's prospects following the loss of its main value driver. A mild risk-off tone in the broader Swedish and U.S. markets provided no support for the embattled micro-cap biotech stock.